Abstract Patients with rheumatoid arthritis (RA) treated with Janus kinase (JAK) inhibitors are at increased risk of herpes zoster (HZ). Although the adjuvanted recombinant zoster vaccine (RZV) is recommended, its immunogenicity and safety under JAK inhibitor therapy remain incompletely characterized. We evaluated humoral and cellular immune responses and safety of RZV in Japanese patients with RA receiving methotrexate (MTX), upadacitinib (UPA), or their combination.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ryuhei
Contact Ryuhei, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack